NL301228I2 - nirsevimab - Google Patents

nirsevimab

Info

Publication number
NL301228I2
NL301228I2 NL301228C NL301228C NL301228I2 NL 301228 I2 NL301228 I2 NL 301228I2 NL 301228 C NL301228 C NL 301228C NL 301228 C NL301228 C NL 301228C NL 301228 I2 NL301228 I2 NL 301228I2
Authority
NL
Netherlands
Prior art keywords
nirsevimab
Prior art date
Application number
NL301228C
Other languages
English (en)
Dutch (nl)
Other versions
NL301228I1 (enExample
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of NL301228I1 publication Critical patent/NL301228I1/nl
Publication of NL301228I2 publication Critical patent/NL301228I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NL301228C 2014-01-15 2023-04-26 nirsevimab NL301228I2 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461927819P 2014-01-15 2014-01-15
PCT/US2015/011391 WO2015108967A2 (en) 2014-01-15 2015-01-14 Rsv-specific antibodies and functional parts thereof

Publications (2)

Publication Number Publication Date
NL301228I1 NL301228I1 (enExample) 2023-05-03
NL301228I2 true NL301228I2 (nl) 2023-09-13

Family

ID=53543612

Family Applications (1)

Application Number Title Priority Date Filing Date
NL301228C NL301228I2 (nl) 2014-01-15 2023-04-26 nirsevimab

Country Status (26)

Country Link
US (6) US20160340414A1 (enExample)
EP (3) EP3094353B1 (enExample)
JP (3) JP6836398B2 (enExample)
KR (1) KR102188437B1 (enExample)
CN (2) CN116355080A (enExample)
AU (4) AU2015206570A1 (enExample)
CA (1) CA2933200C (enExample)
CY (2) CY1123425T1 (enExample)
DK (1) DK3094353T3 (enExample)
ES (1) ES2795727T3 (enExample)
FI (1) FIC20230016I1 (enExample)
FR (1) FR23C1016I2 (enExample)
HR (1) HRP20200607T1 (enExample)
HU (2) HUE048855T2 (enExample)
LT (2) LT3094353T (enExample)
LU (1) LUC00305I2 (enExample)
MX (1) MX374517B (enExample)
NL (1) NL301228I2 (enExample)
NO (1) NO2023016I1 (enExample)
PL (1) PL3094353T3 (enExample)
PT (1) PT3094353T (enExample)
RS (1) RS60387B1 (enExample)
SI (1) SI3094353T1 (enExample)
SM (1) SMT202000282T1 (enExample)
TW (1) TWI705974B (enExample)
WO (1) WO2015108967A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
RS60387B1 (sr) 2014-01-15 2020-07-31 Medimmune Llc Rsv-specifična antitela i njihovi funkcionalni delovi
WO2018075954A2 (en) * 2016-10-21 2018-04-26 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
TWI911431B (zh) * 2017-03-01 2026-01-11 英商梅迪繆思有限公司 抗rsv單株抗體配製物
KR20200140799A (ko) * 2018-01-31 2020-12-16 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 호흡기 세포융합 바이러스에 대하여 사용하기 위한 핵산 항체 작제물
CN111606993B (zh) * 2019-02-26 2022-06-28 中国科学院上海生命科学研究院 抗呼吸道合胞病毒的全人广谱中和抗体4f1及其应用
US12024553B2 (en) 2019-04-30 2024-07-02 Medimmune Limited Dosage regimens for and compositions including anti-RSV antibodies
KR20240055097A (ko) 2021-09-13 2024-04-26 메디뮨 리미티드 니르세비맙을 사용한 호흡기 세포융합 바이러스 하기도 감염의 예방
CN116987183B (zh) * 2022-07-22 2024-10-15 北京智仁美博生物科技有限公司 抗呼吸道合胞病毒中和性抗体及其用途
CN122057014A (zh) * 2024-11-08 2026-05-19 珠海泰诺麦博制药股份有限公司 一种抗rsv抗体在预防和治疗rsv中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
CA2585891A1 (en) * 2004-10-29 2006-05-11 Medimmune, Inc. Methods of preventing and treating rsv infections and related conditions
AU2005335714B2 (en) * 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
SI2066351T1 (sl) 2006-10-02 2016-02-29 E.R. Squibb & Sons, L.L.C. Humana protitelesa, ki vežejo cxcr4 in njihova uporaba
CA2678628A1 (en) 2007-03-06 2008-09-12 Symphogen A/S Recombinant antibodies for treatment of respiratory syncytial virus infections
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
US20110008329A1 (en) * 2007-06-26 2011-01-13 Medlmmune, Llc Methods of Treating RSV Infections And Related Conditions
US8092804B2 (en) * 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
ES2579231T3 (es) 2008-01-15 2016-08-08 Abbvie Inc Vectores de expresión de mamíferos mejorados y usos de los mismos
WO2011008093A1 (en) * 2009-07-15 2011-01-20 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
MX2012001882A (es) * 2009-08-13 2012-04-11 Crucell Holland Bv Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso.
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
WO2011043643A1 (en) * 2009-10-06 2011-04-14 Medimmune Ltd Rsv-specific binding molecule
US20120263715A1 (en) 2009-10-28 2012-10-18 Medimmune, Llc Topical Methods Of Treating RSV Infections And Related Conditions
EP2591000B1 (en) * 2010-07-09 2017-05-17 Janssen Vaccines & Prevention B.V. Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
AU2013234046B2 (en) * 2012-03-16 2017-09-07 University Health Network Methods and compositions for modulating Toso activity
US20150158942A1 (en) * 2012-05-22 2015-06-11 Shire Human Genetic Therapies, Inc. Anti-ccl2 antibodies for treatment of scleroderma
RS60056B1 (sr) 2013-02-01 2020-04-30 Medimmune Llc Epitopi f proteina respiratornog sincicijalnog virusa
RS60387B1 (sr) 2014-01-15 2020-07-31 Medimmune Llc Rsv-specifična antitela i njihovi funkcionalni delovi
JP2020509025A (ja) 2017-03-01 2020-03-26 メドイミューン・リミテッドMedImmune Limited モノクローナル抗体製剤
TWI911431B (zh) 2017-03-01 2026-01-11 英商梅迪繆思有限公司 抗rsv單株抗體配製物

Also Published As

Publication number Publication date
WO2015108967A8 (en) 2015-10-01
LT3094353T (lt) 2020-08-10
BR112016015044A2 (pt) 2017-09-19
CA2933200A1 (en) 2015-07-23
MX2016008639A (es) 2017-02-15
BR112016015044A8 (pt) 2023-04-11
US20250179153A1 (en) 2025-06-05
US12173050B2 (en) 2024-12-24
EP4353316A2 (en) 2024-04-17
CY2023011I1 (el) 2023-11-15
DK3094353T3 (da) 2020-06-02
AU2025201056A1 (en) 2025-03-06
SI3094353T1 (sl) 2020-07-31
KR102188437B1 (ko) 2020-12-08
AU2021204339A1 (en) 2021-07-22
CY2023011I2 (el) 2023-11-15
US20230365660A1 (en) 2023-11-16
AU2015206570A1 (en) 2016-07-14
JP2025063143A (ja) 2025-04-15
AU2020203831A1 (en) 2020-07-02
JP2023052693A (ja) 2023-04-11
EP3741390A1 (en) 2020-11-25
EP3094353B1 (en) 2020-04-01
WO2015108967A2 (en) 2015-07-23
RU2016133247A (ru) 2018-02-20
ES2795727T3 (es) 2020-11-24
JP2020103293A (ja) 2020-07-09
CA2933200C (en) 2025-05-06
LUC00305I2 (enExample) 2025-09-22
EP4353316A3 (en) 2024-08-21
HUS2300019I1 (hu) 2023-05-28
LTPA2023514I1 (enExample) 2023-05-25
RS60387B1 (sr) 2020-07-31
WO2015108967A3 (en) 2015-09-03
US11661449B2 (en) 2023-05-30
JP6836398B2 (ja) 2021-03-03
FIC20230016I1 (fi) 2023-04-26
PL3094353T3 (pl) 2020-09-07
EP3094353A2 (en) 2016-11-23
FR23C1016I1 (fr) 2023-06-23
EP3094353A4 (en) 2017-09-06
NL301228I1 (enExample) 2023-05-03
NO2023016I1 (no) 2023-04-25
US20220098285A1 (en) 2022-03-31
US20160340414A1 (en) 2016-11-24
TWI705974B (zh) 2020-10-01
PT3094353T (pt) 2020-06-08
CY1123425T1 (el) 2021-12-31
MX374517B (es) 2025-03-06
LTC3094353I2 (enExample) 2025-07-10
US11186628B2 (en) 2021-11-30
US20190106482A1 (en) 2019-04-11
CN105916520A (zh) 2016-08-31
KR20160104018A (ko) 2016-09-02
TW201612191A (en) 2016-04-01
HUE048855T2 (hu) 2020-08-28
HRP20200607T1 (hr) 2020-07-10
US10689437B2 (en) 2020-06-23
US20200331989A1 (en) 2020-10-22
CN116355080A (zh) 2023-06-30
JP2017504321A (ja) 2017-02-09
RU2016133247A3 (enExample) 2019-01-16
HK1225992A1 (en) 2017-09-22
FR23C1016I2 (fr) 2026-05-29
AU2021204339B2 (en) 2024-11-14
SMT202000282T1 (it) 2020-07-08
ES2795727T9 (en) 2026-01-21

Similar Documents

Publication Publication Date Title
DK3183051T3 (da) Væske-til-luftmembranenergivekslere
DK3134402T3 (da) 4-amino-imidazoquinolinforbindelser
DK3211743T3 (da) Ø-til-netværk-omskiftningsfremgangsmåde
DK3006072T3 (da) Karadgang
DK3222714T3 (da) Phytasemutanter
DK3119396T3 (da) Muscarinreceptoragonister
FIC20230016I1 (fi) Nirsevimabi
EP3230438C0 (en) N-GLYCOSYLATION
EP4011484C0 (en) CARBONIC ANHYDRASE OF THERMOVIBRIO AMMONIFICANS
DK4242916T3 (da) Forstøver
DK3183340T3 (da) Termolabile exonukleaser
DK3154703T3 (da) Fuldkappe-snekkecentrifuge
DE112015005041A5 (de) Gargerätevorrichtung
DK3110439T3 (da) Pcsk9-vacciner
DE102014000623A8 (de) Halbhohlnietelement
DK3009858T3 (da) Skyradar
DE202014005655U8 (de) llluminationsvorrichtung
DE112015001633A5 (de) Betätigungsaktuator
DK3447493T3 (da) Proteinrettede ortologer
ES1133830Y (es) Columbario
DE112015005055A5 (de) Gargerätevorrichtung
DK3091875T3 (da) Vipbar taburet
ES1129430Y (es) Embalaje-contenedor
ES1114205Y (es) Heliostato
DK3191825T3 (da) Kreatininbiosensor